Psychotic symptoms manifest in up to 50% of patients with dementia and 34% of the nursing home population. First-generation, or conventional, antipsychotic agents have been used to treat both psychotic and behavioral disturbances associated with dementia, but these agents are limited by high rates of EPS and TD as well as incomplete efficacy. With the exception of risperidone, the second-generation (atypical) antipsychotics generally demonstrate a lower EPS liability. However, a number of drug-specific adverse effects remain a concern in this sensitive population. This presentation will examine the available evidence on the efficacy, safety, and tolerability of second-generation agents with a view towards overall effectiveness in the geriatric population.
Back to S103 Effective Management of Patients with Dementia and Psychotic Symptoms
Back to Satellite Symposia
Back to The Eleventh International Congress